[1] Shang S, Zhou D, Ya J, Li S, Yang Q, Ding Y, Ji X, Meng R. Progress in moyamoya disease[J]. Neurosurg Rev, 2020, 43:371-382. [2] Kuroda S, Fujimura M, Takahashi J, Kataoka H, Ogasawara K, Iwama T, Tominaga T, Miyamoto S; Research Committee on Moyamoya Disease (Spontaneous Occlusion of Circle of Willis) of the Ministry of Health, Labor, and Welfare, Japan. Diagnostic criteria for moyamoya disease:2021 revised version[J]. Neurol Med Chir (Tokyo), 2022, 62:307-312. Kobayashi H, [3] Ihara M, Yamamoto Y, Hattori Y, Liu W, Ishiyama H, Yoshimoto T, Miyawaki S, Clausen T, Bang OY, Steinberg GK, Tournier-Lasserve E, Koizumi A. Moyamoya disease:diagnosis and interventions[J]. Lancet Neurol, 2022, 21:747-758. [4] Demartini Z Jr, Teixeira BC, Koppe GL, Gatto LAM, Roman A, Munhoz RP. Moyamoya disease and syndrome:a review[J]. Radiol Bras, 2022, 55:31-37. [5] Zhang X, Xiao W, Zhang Q, Xia D, Gao P, Su J, Yang H, Gao X, Ni W, Lei Y, Gu Y. Progression in moyamoya disease:clinical features, neuroimaging evaluation, and treatment[J]. Curr Neuropharmacol, 2022, 20:292-308. [6] Fang YC, Wei LF, Hu CJ, Tu YK. Pathological circulating factors in moyamoya disease[J]. Int J Mol Sci, 2021, 22:1696. [7] Sudhir BJ, Keelara AG, Venkat EH, Kazumata K, Sundararaman A. The mechanobiological theory:a unifying hypothesis on the pathogenesis of moyamoya disease based on a systematic review[J]. Neurosurg Focus, 2021, 51:E6. M, [8] Velo M, Grasso G, Fujimura M, Torregrossa F, Longo Granata F, Pitrone A, Vinci SL, Ferraù L, La Spina P. Moyamoya vasculopathy:cause, clinical manifestations, neuroradiologic features, and surgical management[J]. World Neurosurg, 2022, 159:409-425. Wanebo JE. [9] Fox BM, Dorschel KB, Lawton MT, Pathophysiology of vascular stenosis and remodeling in moyamoya disease[J]. Front Neurol, 2021, 12:661578. [10] Fujimura M, Tominaga T, Kuroda S, Takahashi JC, Endo H, Ogasawara K, Miyamoto S; Research Committee on Moyamoya Disease (Spontaneous Occlusion of Circle of Willis) of the Ministry of Health, Labor Welfare, Japan; Guideline Committee 2021 of the Japan Stroke Society. 2021 Japanese Guidelines for the Management of Moyamoya Disease:Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society[J]. Neurol Med Chir (Tokyo), 2022, 62:165-170. [11] Funaki T. Moyamoya disease[J]. No Shinkei Geka, 2021, 49:262-270. [12] He S, Duan R, Liu Z, Ye X, Yuan L, Li T, Tan C, Shao J, Qin S, Wang R. Characteristics of cognitive impairment in adult asymptomatic moyamoya disease[J]. BMC Neurol, 2020, 20:322. [13] Shi Z, Wen YJ, Huang Z, Yu LB, Zhang D. Different aspects of cognitive function in adult patients with moyamoya disease and its clinical subtypes[J]. Stroke Vasc Neurol, 2020, 5:86-96. GK, [14] Zeifert PD, Karzmark P, Bell-Stephens TE, Steinberg Dorfman LJ. Neurocognitive performance after cerebral revascularization in adult moyamoya disease[J]. Stroke, 2017, 48:1514-1517. [15] Appireddy R, Ranjan M, Durafourt BA, Riva-Cambrin J, Hader WJ, Adelson PD. Surgery for moyamoya disease in children[J]. J Child Neurol, 2019, 34:517-529. [16] Uchida S, Kubo Y, Oomori D, Yabuki M, Kitakami K, Fujiwara S, Yoshida K, Kobayashi M, Terasaki K, Ogasawara K. Long-term cognitive changes after revascularization surgery in adult patients with ischemic moyamoya disease[J]. Cerebrovasc Dis Extra, 2021, 11:145-154. [17] Yabuki M, Kubo Y, Kitakami K, Oomori D, Fujiwara S, Yoshida K, Kobayashi M, Ogasawara K. Development of cerebral microbleeds and its impact on cognitive function in adult patients receiving medical management alone for ischemic moyamoya disease:supplementary analysis of a 5-year prospective cohort[J]. Neurol Res, 2022, 44:1104-1112. [18] Kuroda S, Kashiwazaki D, Hirata K, Shiga T, Houkin K, Tamaki N. Effects of surgical revascularization on cerebral oxygen metabolism in patients with moyamoya disease:an 15O-gas positron emission tomographic study[J]. Stroke, 2014, 45:2717-2721. [19] Matsushima Y, Inaba Y. Moyamoya disease in children and its surgical treatment:introduction of a new surgical procedure and its follow-up angiograms[J]. Childs Brain, 1984, 11:155-170. [20] Gupta SK, Narayanan R, Aggarwal A, Mohanty M, Ahuja C, Verma N, Praneeth K, Agarwal V. Outcome following surgical revascularization in patients of moyamoya disease with focus on graft patency and angiographic changes[J]. Neurol India, 2021, 69:620-627. [21] Zhang XH, Song CX, Wang WY, Li YZ, Zhao HH, Yang J, Shang JX, Yan XT, Chen GJ, Jiao XJ. Effect of Kaiqiao Tongluo Decoction on cognitive dysfunction caused by cerebral small vessel disease and its influence on heat shock protein 70 and vascular endothelial growth factor[J]. Xian Dai Zhong Xi Yi Jie He Za Zhi, 2019, 30:2759-2763.[张晓慧, 宋彩霞, 王文艳, 李永章, 赵红红, 杨杰, 尚杰雄, 闫薪庭, 陈国杰, 焦小杰. 开窍通络汤治疗脑小血管病致认知功能障碍效果及对热休克蛋白70和血管内皮生长因子的影响[J]. 现代中西医结合杂志, 2019, 30:2759-2763.] [22] Nguyen VN, Parikh KA, Motiwala M, Erin Miller L, Barats M, Milton C, Khan NR. Surgical techniques and indications for treatment of adult moyamoya disease[J]. Front Surg, 2022, 9:966430. [23] Zhao Y, Yu S, Lu J, Yu L, Li J, Zhang Y, Zhang D, Wang R, Zhao Y. Direct bypass surgery vs. combined bypass surgery for hemorrhagic moyamoya disease:a comparison of angiographic outcomes[J]. Front Neurol, 2018, 9:1121. 50 years[J]. [24] Wang DH, Wang F. Cerebrovascular bypass in Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2022, 22:331-334.[王东海, 王飞. 脑血管搭桥术50年[J]. 中国现代神经疾病杂志, 2022, 22:331-334.] [25] Cho WS, Kim JE, Kim CH, Ban SP, Kang HS, Son YJ, Bang JS, Sohn CH, Paeng JC, Oh CW. Long-term outcomes after combined revascularization surgery in adult moyamoya disease[J]. Stroke, 2014, 45:3025-3031. [26] Czabanka M, Peña-Tapia P, Scharf J, Schubert GA, Münch E, Horn P, Schmiedek P, Vajkoczy P. Characterization of direct and indirect cerebral revascularization for the treatment of European patients with moyamoya disease[J]. Cerebrovasc Dis, 2011, 32:361-369. Li Q, Tong XG. Clinical analysis of [27] Wang BL, Sun Y, superficial temporal artery-middle cerebral artery bypass combined with temporoparietal fascia in the treatment of moyamoya disease[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2022, 22:368-373.[王本琳, 孙杨, 李琪, 佟小光. 颞浅动脉-大脑中动脉搭桥术联合带蒂颞顶筋膜瓣贴敷术治疗烟雾病疗效分析[J]. 中国现代神经疾病杂志, 2022, 22:368-373.] [28] Deng X, Gao F, Zhang D, Zhang Y, Wang R, Wang S, Cao Y, Zhao Y, Pan Y, Ye X, Liu X, Zhang Q, Wang J, Yang Z, Zhao M, Zhao J. Effects of different surgical modalities on the clinical outcome of patients with moyamoya disease:a prospective cohort study[J]. J Neurosurg, 2018, 128:1327-1337. [29] Zeng H, Guo Y, Li Y, Yu X, Yan F, Tan X, Xu H, Peng Y, Zhuang J, Zhou H, Fu X, Wang L, Chen G. Comparison of operative and conservative treatment for asymptomatic moyamoya disease:preliminary experience in small retrospective series[J]. World Neurosurg, 2021, 146:e955-960. [30] Bot GM, Burkhardt JK, Gupta N, Lawton MT. Superficial temporal artery-to-middle cerebral artery bypass in combination with indirect revascularization in moyamoya patients ≤ 3 years of age[J]. J Neurosurg Pediatr, 2018, 23:198-203. [31] Baek HJ, Chung SY, Park MS, Kim SM, Park KS, Son HU. Preliminary study of neurocognitive dysfunction in adult moyamoya disease and improvement after superficial temporal artery-middle cerebral artery bypass[J]. J Korean Neurosurg Soc, 2014, 56:188-193. [32] Kimura K, Kubo Y, Dobashi K, Katakura Y, Chida K, Kobayashi M, Yoshida K, Fujiwara S, Terasaki K, Kawamura T, Ogasawara K. Angiographic, cerebral hemodynamic, and cognitive outcomes of indirect revascularization surgery alone for adult patients with misery perfusion due to ischemic moyamoya disease[J]. Neurosurgery, 2022, 90:676-683. [33] Sun J, Li ZY, Chen C, Ling C, Li H, Wang H. Postoperative neovascularization, cerebral hemodynamics, and clinical prognosis between combined and indirect bypass revascularization procedures in hemorrhagic moyamoya disease[J]. Clin Neurol Neurosurg, 2021, 208:106869. [34] Qian C, Yu X, Li J, Chen J, Wang L, Chen G. The efficacy of surgical treatment for the secondary prevention of stroke in symptomatic moyamoya disease:a meta-analysis[J]. Medicine (Baltimore), 2015, 94:e2218. [35] Acker G, Fekonja L, Vajkoczy P. Surgical management of moyamoya disease[J]. Stroke, 2018, 49:476-482. [36] Expert Consensus Group on Vascular Cognitive Impairment. Expert consensus on vascular cognitive impairment[J]. Zhonghua Nei Ke Za Zhi, 2007, 46:1052-1055.[血管性认知功能损害专家共识组. 血管性认知功能损害的专家共识[J]. 中华内科杂志, 2007, 46:1052-1055.] [37] Lugtmeijer S, Lammers NA, de Haan EHF, de Leeuw FE, Kessels RPC. Post-stroke working memory dysfunction:a meta-analysis and systematic review[J]. Neuropsychol Rev, 2021, 31:202-219. [38] Karzmark P, Zeifert PD, Bell-Stephens TE, Steinberg GK, Dorfman LJ. Neurocognitive impairment in adults with moyamoya disease without stroke[J]. Neurosurgery, 2012, 70:634-638. [39] Friedman NP, Robbins TW. The role of prefrontal cortex in cognitive control and executive function[J]. Neuropsychopharmacology, 2022, 47:72-89. [40] Liang X, Zou Q, He Y, Yang Y. Topologically reorganized connectivity architecture of default-mode, executive-control, and salience networks across working memory task loads[J]. Cereb Cortex, 2016, 26:1501-1511. [41] Lei Y, Li YJ, Guo QH, Liu XD, Liu Z, Ni W, Su JB, Yang H, Jiang HQ, Xu B, Gu YX, Mao Y. Postoperative executive function in adult moyamoya disease:a preliminary study of its functional anatomy and behavioral correlates[J]. J Neurosurg, 2017, 126:527-536. [42] Visintin E, De Panfilis C, Antonucci C, Capecci C, Marchesi C, Sambataro F. Parsing the intrinsic networks underlying attention:a resting state study[J]. Behav Brain Res, 2015, 278:315-322. [43] Migliaccio R, Boutet C, Valabregue R, Ferrieux S, Nogues M, Lehéricy S, Dormont D, Levy R, Dubois B, Teichmann M. The brain network of naming:a lesson from primary progressive aphasia[J]. PLoS One, 2016, 11:e0148707. [44] Dafni-Merom A, Peters-Founshtein G, Kahana-Merhavi S, Arzy S. A unified brain system of orientation and its disruption in Alzheimer's disease[J]. Ann Clin Transl Neurol, 2019, 6:2468-2478. [45] Kaminski J, Bowren M Jr, Manzel K, Tranel D. Neural correlates of recognition and naming of famous persons and landmarks:a special role for the left anterior temporal lobe[J]. Handb Clin Neurol, 2022, 187:303-317. [46] Wendelken C, Ferrer E, Whitaker KJ, Bunge SA. Fronto-parietal network reconfiguration supports the development of reasoning ability[J]. Cereb Cortex, 2016, 26:2178-2190. |